Highlights
1 patent
About
Slowing Cancer Progression via the Thyroid Gland
Musli Thyropeutics offers a treatment that induces hypofunction of the thyroid gland in order to slow and inhibit cancer progression and enhance the efficacy of chemotherapy and radiotherapy. Current research is based on induction of hypothyroxinemia adjunct to conventional therapies in glioblastoma multiforme patients. The treatment's safety and efficacy are also being assessed, and the research is supported by the Tel Aviv Sourasky Medical Center.
Identity
| Name | Musli Thyropeutics |
|---|---|
| Slug | musli-thyropeutics |
| Type / kind | startup |
| Crunchbase ID | musli-thyropeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwMiCjd8IDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2021 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tzur Moshe |
| HQ address | HaGefen 6, Zur Moshe, Israel |
Web & social
| Website | http://www.musli.co.il/ |
|---|---|
| https://www.linkedin.com/company/15152387 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business models
B2B
Tags
cancertreatments
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}